Crişan Marilena, Nanulescu Mircea, Panţa Paraschiva Cherecheş, Popa Mirela, Farcău Mihaela, Mureşan Mariana, Ichim Gabriela
Spitalul Clinic de Copii, Oradea.
Pneumologia. 2008 Jul-Sep;57(3):158-60, 162, 164.
Studies have demonstrated growth suppressive effects in case of use of inhaled corticosteroids therapy.
To assess growth velocity during 12 months of inhaled corticosteroids therapy in children with persistent asthma.
Measurements of height were performed in the study group including 109 children with mild and moderately severe, persistent asthma, after 12 month with low or medium doses of either beclomethasone dipropionate or fluticasone propionate. The results were compared with a control group including 71 children with asthma treated with montelukast or cromones.
There were statistically significant differences between study group and controls concerning the growth velocity after 3 months of inhaled glucocorticoid therapy (GSI).
The velocity of growth was decreased in the study group compared to controls after 3 months of treatment, but the differences become unsignificant after 12 months of therapy.
研究表明吸入性糖皮质激素治疗具有生长抑制作用。
评估持续性哮喘儿童吸入性糖皮质激素治疗12个月期间的生长速度。
对109名轻度和中度重度持续性哮喘儿童的研究组进行身高测量，这些儿童在使用低剂量或中等剂量的二丙酸倍氯米松或丙酸氟替卡松治疗12个月后进行测量。将结果与包括71名接受孟鲁司特或色酮治疗的哮喘儿童的对照组进行比较。
吸入糖皮质激素治疗（GSI）3个月后，研究组与对照组在生长速度方面存在统计学上的显著差异。
治疗3个月后，研究组的生长速度与对照组相比有所下降，但治疗12个月后差异变得不显著。
